RT Journal Article
SR Electronic
T1 IMPACT OF CONDITIONING INTENSITY AND GENOMICS ON RELAPSE AFTER ALLOGENEIC TRANSPLANTATION FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.25.20138461
DO 10.1101/2020.08.25.20138461
A1 Dillon, Laura W.
A1 Gui, Gege
A1 Logan, Brent R.
A1 Fei, Mingwei
A1 Ghannam, Jack
A1 Li, Yuesheng
A1 Licon, Abel
A1 Alyea, Edwin P.
A1 Bashey, Asad
A1 Devine, Steven M.
A1 Fernandez, Hugo F.
A1 Giralt, Sergio
A1 Hamadani, Mehdi
A1 Howard, Alan
A1 Maziarz, Richard T.
A1 Porter, David L.
A1 Warlick, Erica D.
A1 Pasquini, Marcelo C.
A1 Scott, Bart L.
A1 Horwitz, Mitchell E.
A1 Deeg, H. Joachim
A1 Hourigan, Christopher S.
YR 2020
UL http://medrxiv.org/content/early/2020/08/31/2020.08.25.20138461.abstract
AB Myelodysplastic Syndrome (MDS) patients are at risk of relapse after allogeneic hematopoietic cell transplantation (alloHCT). The utility of ultra-deep genomic testing to predict, and the impact of conditioning intensity to prevent, MDS relapse are unknown. Targeted error-corrected DNA sequencing was performed on pre-conditioning blood samples from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 phase III randomized clinical trial which compared outcomes by alloHCT conditioning intensity in adult patients with less than 5% marrow myeloblasts and no leukemic myeloblasts in blood on morphological analysis at the time of pre-transplant assessment. Using a previously described set of 10 gene regions, 42% of patients had mutations detectable prior to randomization to reduced intensity or myeloablative conditioning. Testing positive was associated with increased rates of relapse and decreased overall survival. In those testing positive, relapse rates were higher and relapse-free survival was lower in reduced intensity versus myeloablative conditioning arms. Testing additional genes, including those associated with MDS, did not improve prognostication. This study provides evidence that post-transplant relapse rates in MDS patients are highest in those with pre-transplant genomic evidence of high-risk disease. In those testing positive, randomization to myeloablative conditioning lowered but did not eliminate relapse risk.Competing Interest StatementCSH: Research support; Merck, Sellas, Qiagen and ArcherDx. SG: Research support: Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Omeros, Takeda. Advisory Boards: Amgen, Actinuum, Celgene, Johnson & Johnson, Jazz Pharmaceutical, Kite, Novartis, Spectrum Pharma, Takeda. RTM: Honoraria: Novartis, Incyte, Juno Therapeutics, and Kite Therapeutics; Scientific Steering Committee membership for trials with Novartis Pharmaceuticals Corporation; Patents and royalties: Athersys, Inc; MEH: Research support; Gamida Cell, Incyte. Consultancy; Abbvie. HFF: Advisory Boards: Incyte and Jazz Pharmaceuticals; Speakers Bureau: SanofiFunding StatementThis work was supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and by grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) from the NHLBI and the National Cancer Institute (NCI). The CIBMTR registry is supported primarily by the U24-CA76518 from NHLBI, NCI and the National Institute of Allergy and Infectious Diseases and from HHSH234200637015C (HRSA/DHHS) to the Center for International Blood and Marrow Transplant Research. This study utilized BMT CTN 0901 research materials, biospecimens and clinical trial data, provided by the BMT CTN.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients provided written informed consent to participate in both the BMT CTN 0901 trial and the CIBMTR research database. This study was approved by the BMT CTN and CIBMTR and conducted with approval of the National Marrow Donor Program institutional review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDNA sequencing FASTQ files are available in the NCBI Small Reads Archive (SRA)